Introducing Precision Addiction Management of Reward Deficiency Syndrome, the Construct That Underpins All Addictive Behaviors

  title={Introducing Precision Addiction Management of Reward Deficiency Syndrome, the Construct That Underpins All Addictive Behaviors},
  author={Kenneth Blum and Marjorie C Gondr{\'e}-Lewis and David Baron and Panayotis K. Thanos and Eric R. Braverman and Jennifer L. Neary and Igor Elman and Rajendra D. Badgaiyan},
  journal={Frontiers in Psychiatry},
These basic concepts underpin translational addiction-related research that can help the multitude of victims of genetically induced RDS become the recipients of better therapeutic relapse-preventive tactics. Finally, as neuroscientists and psychiatrists, working in the “addiction space” we encourage the global scientific community to take heed and reconsider the current utilization of dopaminergic blockade and instead adopt the goal of regaining dopamine homeostasis. Optimistically, early… 

Figures from this paper

A Novel Precision Approach to Overcome the “Addiction Pandemic” by Incorporating Genetic Addiction Risk Severity (GARS) and Dopamine Homeostasis Restoration
RDS methodology holds a strong promise for reducing the burden of addictive disorders for individuals, their families, and society as a whole by guiding the restoration of dopamine homeostasisthrough anti-reward allostatic neuroadaptations.
Overcoming reward deficiency syndrome by the induction of “dopamine homeostasis” instead of opioids for addiction: illusion or reality?
Various potential therapeutic modalities are discussed that can provide dopamine homeostasis via activation of dopaminergic pathways and viewing reward deficiency syndrome through this osteopathic lens can bring about treatments that aim to restore the dopamineHomeostasis.
A Systems Biological Approach Coupling Reward Gene Polymorphisms and aNutraceutical (KB220Z) Pro-Dopamine Regulator (PDR) as Putative“Standard of Care” to Treat Reward Deficiency Syndrome (RDS): EmergingEvidence - Based Scientific Induction of “Dopamine Homeostasis”
It is proposed that, in order to successfully combat the widespread abuse of drugs and even non-drug behaviors (e.g. gambling etc.), one option, is to consider induction of “dopamine homeostasis” WC 285.
Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD)
It is envisaged that GARS type of screening will provide a novel opportunity to help identify causal pathways and associated mechanisms of genetic factors, psychological characteristics, and addictions awaiting additional scientific evidence including a future meta- analysis of all available data.
Genetic variation in alcoholism and opioid addiction susceptibility and treatment: a pharmacogenomic approach
Current knowledge, treatments, and research regarding genetic predisposition to alcoholism are outlined, focusing on pharmacodynamic variation within the dopaminergic system and shared implications for opioid abuse.
Reward Deficiency Syndrome (RDS) Surprisingly Is Evolutionary and Found Everywhere: Is It “Blowin’ in the Wind”?
The hypothesis is that the true phenotype is RDS, and behavioral disorders are endophenotypes, with an array of many neurotransmitters and polymorphic loci influencing behavioral functionality.
Should We Embrace the Incorporation of Genetically Guided "Dopamine Homeostasis" in the Treatment of Reward Deficiency Syndrome (RSD) as a Frontline Therapeutic Modality?
The take home message is the plausible acceptance of the well-established evidence for hypodopaminergia, a blunted reward processing system, reduced resting state functional connectivity, genetic antecedents, anti- reward symptomatology, poor compliance with MAT, and generalized RDS.
Neuropharmacological and Neurogenetic Correlates of Opioid Use Disorder (OUD) As a Function of Ethnicity: Relevance to Precision Addiction Medicine
It is proposed that ethnicity/ancestry-informed genetic variations must be analyzed to provide real precision-guided therapeutics with the intent to attenuate this uncontrollable fatal epidemic of opioid addictions.
Hypodopaminergia and "Precision Behavioral Management" (PBM): It is a Generational Family Affair.
This three-generation case series represents an example of the impact of both genetic information coupled with an appropriate DNA guided "Pro-Dopamine Regulator" in recovery and enhancement of life.
Precision Behavioral Management (PBM) and Cognitive Control as a Potential Therapeutic and Prophylactic Modality for Reward Deficiency Syndrome (RDS): Is There Enough Evidence?
Current and future advances, concepts, and the substantial evidential basis of this potential therapeutic and prophylactic treatment modality are presented.


Genetic addiction risk score (GARS) ™, a predictor of vulnerability to opioid dependence.
The Genetic Addiction Risk Score (GARS) is examined, the first test to accurately predict vulnerability to pain, addiction, and other compulsive behaviors, defined as Reward Deficiency Syndrome (RDS).
Neurogenetics and Nutrigenomics of Neuro-Nutrient Therapy for Reward Deficiency Syndrome (RDS): Clinical Ramifications as a Function of Molecular Neurobiological Mechanisms.
This is a review, with some illustrative case histories from a number of addiction professionals, of certain molecular neurobiological mechanisms which if ignored may lead to clinical complications.
Fifty Years in the Development of a Glutaminergic-Dopaminergic Optimization Complex (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome: A Pictorial.
Dopamine along with other chemical messengers like serotonin, cannabinoids, endorphins and glutamine, play significant roles in brain reward processing. There is a devastating opiate/opioid
Reward deficiency syndrome: genetic aspects of behavioral disorders.
rsfMRI effects of KB220Z™ on neural pathways in reward circuitry of abstinent genotyped heroin addicts
These results and other quantitative electroencephalogy study results suggest a putative anti-craving/anti-relapse role of KB220Z in addiction by direct or indirect dopaminergic interaction.
Overcoming qEEG Abnormalities and Reward Gene Deficits during Protracted Abstinence in Male Psychostimulant and Polydrug Abusers Utilizing Putative Dopamine D2 Agonist Therapy: Part 2
This seminal work is proposing that with necessary large populations supporting these initial results, and possibly even additional candidate genes and single nucleotide polymorphisms, the authors may eventually have the clinical ability to classify severity according to genotype and possession of risk alleles, along with offering a safe, nonaddicting, natural dopaminergic receptor agonist.
The Reward Deficiency Syndrome: A Biogenetic Model for the Diagnosis and Treatment of Impulsive, Addictive and Compulsive Behaviors
In order to explain the breakdown of the reward cascade due to both multiple genes and environmental stimuli (pleiotropism) and resultant aberrant behaviors, Blum united this hypodopaminergic trait under the rubric of a reward deficiency syndrome.
Dopamine homeostasis: brain functional connectivity in reward deficiency syndrome.
It is hypothesize in the present review that loss of homeostasis of these systems may lead to 'unbalanced' functional networks that might be both cause and outcome of disrupted synaptic communication between cortical and subcortical systems essential for controlling reward, emotional control, sensation seeking, and chronic drug use.
Dual dopamine/serotonin releasers: potential treatment agents for stimulant addiction.
It is concluded that DA/5-HT releasers could be useful therapeutic adjuncts for the treatment of cocaine and alcohol addictions, as well as for obesity, attention-deficit disorder, and depression.